Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia With Losing Major Molecular Response as a Definition for Molecular Relapse: A Systematic Review and Meta-Analysis
出版年份 2019 全文链接
标题
Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia With Losing Major Molecular Response as a Definition for Molecular Relapse: A Systematic Review and Meta-Analysis
作者
关键词
-
出版物
Frontiers in Oncology
Volume 9, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2019-05-14
DOI
10.3389/fonc.2019.00372
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase
- (2018) François-Xavier Mahon et al. ANNALS OF INTERNAL MEDICINE
- Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan
- (2018) Naoto Takahashi et al. HAEMATOLOGICA
- Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study
- (2018) David M. Ross et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Front-Line Treatment Options for Chronic-Phase Chronic Myeloid Leukemia
- (2018) Neil P. Shah JOURNAL OF CLINICAL ONCOLOGY
- Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
- (2018) Susanne Saussele et al. LANCET ONCOLOGY
- Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan
- (2018) Naoto Takahashi et al. HAEMATOLOGICA
- Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission
- (2018) Monica Bocchia et al. Frontiers in Oncology
- Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
- (2018) Jerald P. Radich et al. Journal of the National Comprehensive Cancer Network
- First-line treatment strategies for newly diagnosed chronic myeloid leukemia: a network meta-analysis
- (2018) Kang-Kang Chen et al. Cancer Management and Research
- Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study
- (2017) Naoto Takahashi et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia
- (2017) Qian Jiang et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results
- (2017) T P Hughes et al. LEUKEMIA
- Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study
- (2017) A Hochhaus et al. LEUKEMIA
- Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study
- (2016) Delphine Rea et al. BLOOD
- Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study
- (2016) S.-E. Lee et al. HAEMATOLOGICA
- Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial
- (2016) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia
- (2016) M Ilander et al. LEUKEMIA
- Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
- (2016) A Hochhaus et al. LEUKEMIA
- Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study
- (2016) S.-E. Lee et al. HAEMATOLOGICA
- Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study
- (2015) Silvia Mori et al. AMERICAN JOURNAL OF HEMATOLOGY
- Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients
- (2015) Massimo Breccia et al. LEUKEMIA RESEARCH
- Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial
- (2015) Jun Imagawa et al. Lancet Haematology
- Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia
- (2014) H. Herrmann et al. BLOOD
- Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors
- (2013) Lorenzo Falchi et al. AMERICAN JOURNAL OF HEMATOLOGY
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
- (2013) M. Baccarani et al. BLOOD
- Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML
- (2013) S. Branford et al. BLOOD
- Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
- (2013) D. M. Ross et al. BLOOD
- Trends in all-cause mortality among patients with chronic myeloid leukemia
- (2013) Andrew M. Brunner et al. CANCER
- Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV
- (2013) Rüdiger Hehlmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease
- (2013) Philippe Rousselot et al. JOURNAL OF CLINICAL ONCOLOGY
- Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib
- (2013) F Efficace et al. LEUKEMIA
- Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population
- (2011) F. Efficace et al. BLOOD
- Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia
- (2011) N. Takahashi et al. HAEMATOLOGICA
- Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
- (2010) François-Xavier Mahon et al. LANCET ONCOLOGY
- Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia
- (2010) Claude Preudhomme et al. NEW ENGLAND JOURNAL OF MEDICINE
- The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
- (2009) Alessandro Liberati et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More